2 years ago

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

Selumetinib in mix with ZSTK474 or BEZ235 inhibits pERK, pAKT, and pS6 expression

To decide if selumetinib in Idelalisib mix with ZSTK474 or B read more...

2 years ago

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

A66 (36), ZSTK474 (37), BEZ235 (38), TGX-221, and AS-252424 (39) were synthesized at the Auckland Idelalisib, read more...

2 years ago

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

A66 (36), ZSTK474 (37), BEZ235 (38), TGX-221, and AS-252424 (39) were being synthesized at the Auckland Idelalisib, read more...

2 years ago

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

BRAF and MEK inhibitors have enhanced results for individuals with BRAF-mutant melanoma, but their efficacy is Idelalisib limited by each intrinsic and a read more...

2 years ago

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

BRAF and MEK inhibitors have improved outcomes for patients with BRAF-mutant melanoma, but their efficacy is Idelalisib minimal by each intrinsic and acquired re read more...

2 years ago

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

A66 (36), ZSTK474 (37), BEZ235 (38), TGX-221, and AS-252424 (39) ended up synthesized at the Auckland Idelalisib, read more...

2 years ago

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

Selumetinib in combination with ZSTK474 or BEZ235 inhibits pERK, pAKT, and pS6 expression

To determine if selumetinib in Idelalisib combination with Z read more...